Pancreatic Cancer Research

ResearcherMeiwa HospitalActive in the last 2 years

Shinichi Ikuta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9242-8666; OpenAlex author ID A5046584855. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 10

  1. Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity. Co-author DOI 10.21037/jgo-24-147↗
  2. Predicting Pathological Response to Preoperative Chemotherapy in Pancreatic Ductal Adenocarcinoma Using Post-Chemotherapy Computed Tomography Radiomics. Co-author DOI 10.7759/cureus.52193↗
  3. A Liver-First Approach Using Ablation for Oligometastatic Pancreatic Cancer: A Report of a Successful Case. Co-author DOI 10.7759/cureus.46671↗
  4. Impact of the aberrant right hepatic artery on local recurrence of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. First author DOI 10.1016/j.surg.2022.02.010↗
  5. First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Expe… Co-author DOI 10.21873/anticanres.16118↗
  6. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/ajco.13123↗
  7. A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/atm.2019.08.35↗
  8. The preoperative modified Glasgow prognostic score for the prediction of survival after pancreatic cancer resection following non-surgical treatment of an init… Co-author DOI 10.5114/wo.2018.81344↗
  9. Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting. Co-author PMID 26124377↗
  10. Optimal combination of radiofrequency ablation with chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.5306/wjco.v3.i1.12↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoki Yamanaka · 7 shared papers, 2015–2024 · strength 1.17
  2. Takayoshi Nakajima · 4 shared papers, 2018–2024 · strength 0.81
  3. Takashi Sonoda · 4 shared papers, 2015–2022 · strength 0.48
  4. Hiroshi Tsubamoto · 2 shared papers, 2015–2022 · strength 0.23
  5. Abhinav V. Reddy · 1 shared paper, 2024 · strength 0.20
  6. Meng Wang · 1 shared paper, 2024 · strength 0.20
  7. Alice Talbot · 1 shared paper, 2024 · strength 0.20
  8. Wenna Jiang · 1 shared paper, 2024 · strength 0.20
  9. Li Ren · 1 shared paper, 2024 · strength 0.20
  10. Miyuki Sawasaki · 1 shared paper, 2022 · strength 0.17
  11. Hideaki Iwama · 1 shared paper, 2022 · strength 0.16
  12. Etsuro Hatano · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.